SAN DIEGO, CA – July 14, 2022 - Antharis Therapeutics Inc., a biopharmaceutical company developing a leading portfolio of oncology-related immunotherapeutics, announced the completion of its Series A today. The rapid growth of the company since its inception, has placed it at the leading edge of biotechnology companies generating high-potential, next-generation monoclonal antibodies for the treatment of cancer. Antharis’ Series A, one of the largest preclinical financing rounds in the USA this year, was completed in only three weeks and was over-subscribed by tens of millions of dollars.
“Antharis is very pleased by the successful completion of our very successful Series A financing, which will enable us to grow significantly and continue pursuing the development of cutting-edge biotherapeutics for patients in need, globally. In addition, the significant interest of investors in our company has demonstrated not only the power of our platform approach, but the significance and promise of our current pipeline of products under development” said Dr. Raphael Ribeiro-Pinaud, CEO & Chairman of Antharis Therapeutics.
Antharis leverages a platform approach for the discovery, characterization, and validation of monoclonal antibodies for multiple cancer types.This has allowed Antharis to grow one of the largest preclinical portfolios of monoclonal antibodies in the industry and supported the company’s recent acquisition of Cassyni Biopharma in July 2022. Antharis will begin pre-IND work on a selection of its advanced assets this year.
About Antharis Therapeutics
Antharis Therapeutics Inc. is a biopharmaceutical company involved in the discovery and development of immunotherapeutics to address devastating diseases for which there are limited or unsatisfactory treatment options. Antharis is focused on oncological (cancer) diseases, as this is one of the largest markets in need of therapies and where our team has its greatest expertise. Antharis is based in the Greater San Diego Area, California, one of the prime biotechnology hubs in the world and is led by Dr. Raphael Ribeiro-Pinaud, CEO & Chairman. For more information, visit www.antharistherapeutics.com.
